(NASDAQ:ZLAB) SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. “Today’s approval of TIVDAK marks an important milestone for Zai Lab, further strengthening our Women’s franchise in Greater China,” said Andrew Zhu, Chief Commercial Of
Related Questions
How will the Hong Kong approval of TIVDAK impact Zai Lab's revenue forecasts and earnings guidance for the upcoming quarters?
What is the expected market uptake and reimbursement environment for TIVDAK in Greater China versus existing cervical cancer treatments?
How does this approval affect Zai Lab's competitive positioning against other ADCs and immunotherapies in the cervical cancer space, and could it spur partnership or M&A activity?